Last reviewed · How we verify

Nuzyra — Competitive Intelligence Brief

Nuzyra (OMADACYCLINE) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline-class Antibacterial [EPC]. Area: Infectious Disease.

marketed Tetracycline-class Antibacterial [EPC] Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Nuzyra (OMADACYCLINE) — Paratek Pharms. Nuzyra works by inhibiting protein synthesis in bacteria, ultimately leading to their death.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nuzyra TARGET OMADACYCLINE Paratek Pharms marketed Tetracycline-class Antibacterial [EPC] 2018-01-01
Nuzyra OMADACYCLINE TOSYLATE Paratek Pharms marketed Tetracycline-class Antibacterial [EPC] 2018-01-01
Tygacil TIGECYCLINE Fresenius Kabi marketed Tetracycline-class Antibacterial [EPC] 30S ribosomal subunit 2005-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Tetracycline-class Antibacterial [EPC] class)

  1. Paratek Pharms · 2 drugs in this class
  2. Fresenius Kabi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nuzyra — Competitive Intelligence Brief. https://druglandscape.com/ci/omadacycline. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: